JP2024502106A - ｃ－ＭＹＣ ｍＲＮＡ翻訳調節因子及び癌治療におけるそれの使用 - Google Patents

ｃ－ＭＹＣ ｍＲＮＡ翻訳調節因子及び癌治療におけるそれの使用 Download PDF

Info

Publication number
JP2024502106A
JP2024502106A JP2023540948A JP2023540948A JP2024502106A JP 2024502106 A JP2024502106 A JP 2024502106A JP 2023540948 A JP2023540948 A JP 2023540948A JP 2023540948 A JP2023540948 A JP 2023540948A JP 2024502106 A JP2024502106 A JP 2024502106A
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
branched
ring
straight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023540948A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024502106A5 (https=
Inventor
シェパード、デイヴィッド・ウィリアム
ティアニー、ジェイソン・ポール
マンダビ、アヴィアド
アーロイ、アイリス
ワッサーマン、リナ
ワン、ヤオデ
リー、ハイタン
シャインバーガー、ヨニ
Original Assignee
アニマ バイオテック インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アニマ バイオテック インコーポレイテッド filed Critical アニマ バイオテック インコーポレイテッド
Publication of JP2024502106A publication Critical patent/JP2024502106A/ja
Publication of JP2024502106A5 publication Critical patent/JP2024502106A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023540948A 2021-01-05 2022-01-05 ｃ－ＭＹＣ ｍＲＮＡ翻訳調節因子及び癌治療におけるそれの使用 Pending JP2024502106A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL279972 2021-01-05
IL279972A IL279972A (en) 2021-01-05 2021-01-05 Substances that function as modulators of cmyc-mrna translation and their uses in cancer treatment
PCT/US2022/011203 WO2022150316A1 (en) 2021-01-05 2022-01-05 C-myc mrna translation modulators and uses thereof in the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2024502106A true JP2024502106A (ja) 2024-01-17
JP2024502106A5 JP2024502106A5 (https=) 2025-10-07

Family

ID=82358087

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023540948A Pending JP2024502106A (ja) 2021-01-05 2022-01-05 ｃ－ＭＹＣ ｍＲＮＡ翻訳調節因子及び癌治療におけるそれの使用

Country Status (8)

Country Link
US (1) US20220370431A1 (https=)
EP (1) EP4274569A4 (https=)
JP (1) JP2024502106A (https=)
CN (1) CN116635028A (https=)
AU (1) AU2022205591A1 (https=)
CA (1) CA3199333A1 (https=)
IL (2) IL279972A (https=)
WO (1) WO2022150316A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024010761A1 (en) * 2022-07-03 2024-01-11 Anima Biotech Inc. C-myc mrna translation modulators and uses thereof in the treatment of cancer
US12404283B2 (en) 2022-07-03 2025-09-02 Anima Biotech Inc. c-MYC mRNA translation modulators and uses thereof in the treatment of cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998006724A1 (en) * 1996-08-09 1998-02-19 Yamanouchi Pharmaceutical Co., Ltd. Metabotropic glutamate receptor agonists
WO2019131656A1 (ja) * 2017-12-28 2019-07-04 政一 親泊 ベンゾチアゾイミダゾリル化合物を含有する小胞体ストレス調節剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2463774A1 (fr) * 1979-08-21 1981-02-27 Yamanouchi Pharma Co Ltd Derives du 2-phenylimidazo(2,1-b)benzothiazole
US4464384A (en) * 1981-12-23 1984-08-07 Yamanouchi Pharmaceutical Co., Ltd. 2-Phenylimidazo[2,1-b]benzothiazole compounds, salts thereof, process of producing them, and pharmaceutical compositions containing them
KR101449057B1 (ko) * 2006-03-17 2014-10-10 암비트 바이오사이언시즈 코포레이션 질환 치료용 이미다졸로티아졸 화합물
PE20080403A1 (es) * 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
CA2973739A1 (en) * 2015-02-03 2016-03-24 Active Biotech Ab Imidazo[2,1-b]thiazole and 5,6-dihydroimidazo[2,1-b]thiazole derivatives useful as s100-inhibitors
UY37866A (es) * 2017-09-07 2019-03-29 Glaxosmithkline Ip Dev Ltd Nuevos compuestos derivados de benzoimidazol sustituidos que reducen la proteína myc (c-myc) en las células e inhiben la histona acetiltransferasa de p300/cbp.
CN113710663A (zh) * 2019-02-19 2021-11-26 纳罗医疗公司 Myc家族原癌基因蛋白的调节剂

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998006724A1 (en) * 1996-08-09 1998-02-19 Yamanouchi Pharmaceutical Co., Ltd. Metabotropic glutamate receptor agonists
WO2019131656A1 (ja) * 2017-12-28 2019-07-04 政一 親泊 ベンゾチアゾイミダゾリル化合物を含有する小胞体ストレス調節剤

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
"RN:891888-55-4", DATABASE REGISTRY [ONLINE] , JPN7025005157, 11 July 2006 (2006-07-11), ISSN: 0005743964 *
"RN:891896-13-2、RN:891897-09-9等", DATABASE REGISTRY [ONLINE], JPN7025005156, 11 July 2006 (2006-07-11), ISSN: 0005743963 *
"RN:891911-10-7、他全５化合物", DATABASE REGISTRY [ONLINE] , JPN7025005152, 11 July 2006 (2006-07-11), ISSN: 0005743956 *
"RN:891911-87-8、他全４化合物", DATABASE REGISTRY [ONLINE], JPN7025005151, 11 July 2006 (2006-07-11), ISSN: 0005743955 *
"RN:891912-35-9、他全５化合物", DATABASE REGISTRY [ONLINE] , JPN7025005150, 11 July 2006 (2006-07-11), ISSN: 0005743954 *
"RN:891914-99-1、他全７４化合物", ＤＡＴＡＢＡＳＥ ＲＥＧＩＳＴＲＹ 「ＯＮＬＩＮＥ」, JPN7025005148, 11 July 2006 (2006-07-11), ISSN: 0005743952 *
"RN:903167-03-3、他全４化合物", DATABASE REGISTRY [ONLINE] , JPN7025005154, 22 August 2006 (2006-08-22), ISSN: 0005743958 *
"RN:903169-51-7、他全２０化合物", DATABASE REGISTRY [ONLINE], JPN7025005155, 22 August 2006 (2006-08-22), ISSN: 0005743959 *
"RN:931680-67-0、他全１２化合物", DATABASE REGISTRY [ONLINE] , JPN7025005153, 22 April 2007 (2007-04-22), ISSN: 0005743957 *
"RN:931960-83-7、他全３化合物", ＤＡＴＡＢＡＳＥ ＲＥＧＩＳＴＲＹ 「ＯＮＬＩＮＥ」, JPN7025005149, 23 April 2007 (2007-04-23), ISSN: 0005743953 *
AL-TEL, TALEB H. ET AL.: "Rapid Assembly of Polyfunctional Structures Using a One-Pot Five- and Six- Component Sequential Groe", EUROPEAN JOURNAL OF ORGANIC CHEMISTRY, vol. (29), JPN6025049117, 2010, pages 5586 - 5593, ISSN: 0005743951 *
KAPOOR, ARUN ET AL.: "Validation and Characterization of Five Distinct Novel Inhibitors of Human Cytomegalovirus", JOURNAL OF MEDICINAL CHEMISTRY, vol. 63(8), JPN6025049120, 2020, pages 3896 - 3907, ISSN: 0005743962 *
SAYERS, CARLY M. ET AL.: "Identification and characterization of a potent activator of p53-independent cellular senescence via", MOLECULAR PHARMACOLOGY, vol. 83(3), JPN6025049118, 2013, pages 594 - 604, ISSN: 0005743960 *
SERER, MARIA INES ET AL.: ""A high-throughput screening for inhibitors of riboflavin synthase identifies novel antimicrobial co", FEBS JOURNAL, vol. 286(13), JPN6025049119, 2019, pages 2522 - 2535, ISSN: 0005743961 *

Also Published As

Publication number Publication date
IL279972A (en) 2022-08-01
IL303320A (en) 2023-07-01
EP4274569A1 (en) 2023-11-15
CN116635028A (zh) 2023-08-22
EP4274569A4 (en) 2024-12-04
AU2022205591A9 (en) 2024-02-08
CA3199333A1 (en) 2022-07-14
AU2022205591A1 (en) 2023-07-06
US20220370431A1 (en) 2022-11-24
WO2022150316A1 (en) 2022-07-14

Similar Documents

Publication Publication Date Title
DK3080125T3 (en) PRESENT UNKNOWN AZA DERIVATIVE DERIVATIVES AS SELECTIVE HISTONDEACETYLASE (HDAC) INHIBITORS AND PHARMACEUTICAL COMPOSITIONS INCLUDING THESE
US12084420B2 (en) Indoline compounds for inhibiting KIF18A
CA3047106A1 (en) Aminothiazole compounds as c-kit inhibitors
AU2014367284B2 (en) WNT pathway modulators
US20240150343A1 (en) Compound having brd4 inhibitory activity, preparation method therefor and use thereof
JP7030776B2 (ja) アミノピリジン誘導体およびそれらの選択的ａｌｋ－２阻害剤としての使用
JP2023529884A (ja) コラーゲン１翻訳阻害剤及びその使用方法
JP2023513373A (ja) Ｐ２ｘ３修飾薬
WO2019189555A1 (ja) 複素環化合物
JP2024502106A (ja) ｃ－ＭＹＣ ｍＲＮＡ翻訳調節因子及び癌治療におけるそれの使用
KR20230067669A (ko) 2-아미노-3-카르보닐 이미다조피리딘 및 피라졸로피리딘 화합물
JP2023512647A (ja) コラーゲン１翻訳阻害剤およびその使用方法
EP4463452B1 (en) C-myc mrna translation modulators and uses thereof in the treatment of cancer
US12404283B2 (en) c-MYC mRNA translation modulators and uses thereof in the treatment of cancer
JP2025521719A (ja) ｃ－ＭＹＣ ｍＲＮＡ翻訳調節因子及び癌治療におけるその使用
TW202606657A (zh) 新型異雙功能蛋白質降解劑以及包含其的藥物組成物
HK40097285A (zh) Myc家族原癌基因蛋白的调节剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241210

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250915

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251023

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260203